|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||5.52 - 5.88|
|52 Week Range||5.00 - 10.00|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.25|
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit. During the panel, entitled "Gene therapy: a changing regulatory landscape," Mr. Chereau will offer a brief overview of LogicBio and discuss the design of the SUNRISE clinical trial of LB-001 for the treatment of methylmalonic acidemia (MMA). The panel will take place at 9:15 a.m. EDT on Wednesday March 31st.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020 and provided a business update.